- Home
- AEF vs RIGL Comparison
AEF vs RIGL Comparison
Compare AEF & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AEF | RIGL |
|---|---|---|
| Founded | 1989 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.8M | 884.9M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | AEF | RIGL |
|---|---|---|
| Price | $9.80 | $45.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $45.67 |
| AVG Volume (30 Days) | 75.2K | ★ 206.3K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 7.13% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | 0.57 | ★ 1.32 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.75 |
| P/E Ratio | ★ $16.93 | $34.00 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $6.25 | $24.84 |
| 52 Week High | $10.14 | $52.24 |
Technical Indicators
Market Signals| Indicator | AEF | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 53.07 | 48.97 |
| Support Level | $8.75 | $40.05 |
| Resistance Level | $9.67 | $49.50 |
| Average True Range (ATR) | 0.16 | 1.45 |
| MACD | -0.02 | -0.61 |
| Stochastic Oscillator | 35.38 | 17.89 |
Price Performance
Historical ComparisonAbout AEF abrdn Emerging Markets Equity Income Fund Inc.
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a non-diversified closed-end, management investment company. Its investment objective is to seek to provide both current income and long-term capital appreciation. Under normal circumstances, the fund invests a majority of its net assets (plus any borrowings for investment purposes) in emerging markets (excluding China) equity securities. The performance of the fund is measured against the MSCI Emerging Markets ex-China Index. Its investment portfolio consists of equity securities from emerging market companies (excluding China), spanning multiple sectors such as Information Technology, Financials, Industrials, Consumer Discretionary, Real Estate, and others.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.